Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPELINE-RSV-France infant RSV prevention trial
2025-521755-23-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Annecy Genevois
- Start
- Apr 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nirsevimab and RSVpreF vaccine in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Centre Hospitalier Annecy Genevois. Primary endpoint: Symptomatic RSV respiratory tract infection by 12 months. Planned start Apr 2026; status: authorised.
02
Drugs
nirsevimabRSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2025-521755-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521755-23-00.